A Study of [177Lu] Lu-PSMA-XT Injection in Patients With Metastatic Prostate Cancer

This study is testing a new radioactive drug called [177Lu] Lu-PSMA-XT in men with metastatic castration-resistant prostate cancer (prostate cancer that has spread and no longer responds to hormone therapy). The drug targets a protein called PSMA found on prostate cancer cells and delivers radiation directly to them. The study aims to see if this new version is safe and effective. **You may be eligible if...** - You are a man between 18 and 80 years old - You have confirmed prostate cancer that has spread and is no longer responding to hormone therapy (castrate-resistant) - Your PSMA PET/CT scan shows the cancer is PSMA-positive - You have received at least one hormonal therapy (such as enzalutamide or abiraterone) - You have received at least one or two prior rounds of taxane-based chemotherapy, or you are unable to receive chemotherapy - You are in good physical health (ECOG 0 or 1) with a life expectancy of more than 6 months **You may NOT be eligible if...** - You have received prior PSMA-targeted radioligand therapy - You have received certain other radioactive treatments (e.g., radium-223) within the past 6 months - You have known other active cancers - You have cancer spread to the brain - You have uncontrolled infections, heart failure, or serious complications Talk to your doctor to see if this trial is right for you.